Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShort-Term Debt repayments
Ratios

BioNexus Gene Lab (BGLC) Accumulated Depreciation & Amortization (2019 - 2025)

BioNexus Gene Lab's Accumulated Depreciation & Amortization history spans 7 years, with the latest figure at $971148.0 for Q3 2025.

  • For Q3 2025, Accumulated Depreciation & Amortization rose 25.08% year-over-year to $971148.0; the TTM value through Sep 2025 reached $971148.0, up 25.08%, while the annual FY2024 figure was $983153.0, 11.09% up from the prior year.
  • Accumulated Depreciation & Amortization for Q3 2025 was $971148.0 at BioNexus Gene Lab, up from $943747.0 in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $994915.0 in Q1 2025 and bottomed at -$1.7 million in Q1 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $805273.0 (2022), against an average of $291033.3.
  • The largest YoY upside for Accumulated Depreciation & Amortization was 673.6% in 2022 against a maximum downside of 363.36% in 2022.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $574014.0 in 2021, then tumbled by 363.36% to -$1.5 million in 2022, then soared by 158.54% to $885004.0 in 2023, then increased by 11.09% to $983153.0 in 2024, then decreased by 1.22% to $971148.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Accumulated Depreciation & Amortization are $971148.0 (Q3 2025), $943747.0 (Q2 2025), and $994915.0 (Q1 2025).